Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease.
Gang Liu; Ping Men; Wataru Kudo; George Perry; Mark A Smith (Profiled Authors: Perry, George; Smith, Mark A)
Department of Radiology, University of Utah, Salt Lake City, UT 84108, USA. gang.liu@m.cc.utah.edu
Neuroscience letters 2009;455(3):187-90.
Oxidative stress and amyloid-beta are considered major etiological and pathological factors in the initiation and promotion of neurodegeneration in Alzheimer disease (AD). Insomuch as causes of such oxidative stress, transition metals, such as iron and copper, which are found in high concentrations in the brains of AD patients and accumulate specifically in the pathological lesions, are viewed as key contributors to the altered redox state. Likewise, the aggregation and toxicity of amyloid-beta is dependent upon transition metals. As such, chelating agents that selectively bind to and remove and/or "redox silence" transition metals have long been considered as attractive therapies for AD. However, the blood-brain barrier and neurotoxicity of many traditional metal chelators has limited their utility in AD or other neurodegenerative disorders. To circumvent this, we previously suggested that nanoparticles conjugated to iron chelators may have the potential to deliver chelators into the brain and overcome such issues as chelator bioavailability and toxic side-effects. In this study, we synthesized a prototype nanoparticle-chelator conjugate (Nano-N2PY) and demonstrated its ability to protect human cortical neurons from amyloid-beta-associated oxidative toxicity. Furthermore, Nano-N2PY nanoparticle-chelator conjugates effectively inhibited amyloid-beta aggregate formation. Overall, this study indicates that Nano-N2PY, or other nanoparticles conjugated to metal chelators, may provide a novel therapeutic strategy for AD and other neurodegenerative diseases associated with excess transition metals.
1 Originating Grant
-
1.
Smith, Mark A
Amyloid-beta: The Alternate Hypothesis
1 September 2005 - 31 August 2008
NATIONAL INSTITUTE ON AGING
Total Funding: $ 741,057
Scientific Context
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Related Grants
-
1.
SCHMECHEL, DONALD E
AN ANIMAL MODEL OF CHOLINERGIC DEFICIENCY
1 May 1988 - 30 April 1993
NATIONAL INSTITUTE ON AGING
Total Funding: $ 588,660
-
2.
MAYEUX, RICHARD
Epidemiology of Biomarkers of Risk and Progression in LOAD
1 May 2010 - 30 April 2015
NATIONAL INSTITUTE ON AGING
Total Funding: $ 5,932,714
-
3.
MATTSON, MARK
Cellular And Molecular Pathogenesis Of Alzheimer
NATIONAL INSTITUTE ON AGING
Total Funding: $ 2,801,933
Related Publications
-
1.
2006Gang Liu; Ping Men; Peggy L R Harris; Raj K Rolston; George Perry; Mark A Smith
Neuroscience letters 2006;406(3):189-93. -
2.
2009Gang Liu; Ping Men; George Perry; Mark A Smith
Progress in brain research 2009;180():97-108. -
3.
2000L M Sayre; G Perry; P L Harris; Y Liu; K A Schubert; M A Smith
Journal of neurochemistry 2000;74(1):270-9.
Related Topics
Appears in this Publication
Related Experts
Author of this Publication
-
Internal ExpertsPublications
-
540









-
610









-
505









-
411









-
574









-
672










